Pancreatic cancer.

Ammar A Javed, Thomas Seufferlein, Thomas F Stoop, Johanna W Wilmink, Marc G Besselink, Bas Groot Koerkamp, Atsushi Oba

Journal: Lancet (London, England) 2025;405(10485):1182-1202

PMID: 40187844

Full Text on Elsevier Science View on PubMed

Abstract

Pancreatic cancer is frequently a lethal disease with an aggressive tumour biology often presenting with non-specific symptoms. Median survival is approximately 4 months with a 5-year survival of 13%. Surveillance is recommended in individuals with familial pancreatic cancer, specific mutations, and high-risk intraductal papillary mucinous neoplasm, as they are at high risk of developing pancreatic cancer. Chemotherapy combined with surgical resection remains the cornerstone of treatment. However, only a small subset of patients are candidates for surgery. Multi-agent chemotherapy has improved survival in the palliative setting for patients with metastatic disease, as (neo)adjuvant and induction therapy have in patients with borderline resectable and locally advanced pancreatic. Given that pancreatic cancer is predicted to become the second leading cause of cancer-related death by 2030, novel therapies are urgently needed.

Address: Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, Netherlands; Cancer Center Amsterdam, Amsterdam, Netherlands.; Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, Netherlands; Cancer Center Amsterdam, Amsterdam, Netherlands; Division of Surgical Oncology, Department of Surgery, New York University Medical Center, New York, NY, USA.; Department of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan; Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Department of International Medicine I, Ulm University Hospital, Ulm, Germany.; Department of Medical Oncology, Amsterdam, Netherlands; Cancer Center Amsterdam, Amsterdam, Netherlands.; Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, Netherlands; Cancer Center Amsterdam, Amsterdam, Netherlands. Electronic address: [email protected].

DOI: 10.1016/S0140-6736(25)00261-2

Link outs

Free resources

Medical:

https://medlineplus.gov/pancreaticcancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Pancreatic Neoplasms, Pancreatectomy